Healius (HLS)

Simon Turner

Senior Equity Analyst

8 am October 26, 2020


Prior close: $3.67

A great start to the year

Healius (ASX:HLS) provided a strong first quarter update last week, confirming our positive view on the stock. COVID-19 testing generated particularly strong revenue and earnings growth in the company’s pathology operations, and its day hospitals are also performing strongly. Is there more upside in this healthcare group which has been a strong outperformer in recent months?

To read the full report … Become a Member or Login Here

Previous

Next

Register for our FREE reports here...

You have Successfully Subscribed!

Register for our FREE reports here...

You have Successfully Subscribed!